What are determinants of utilisation of pharmaceutical anticancer treatment during the last year of life in Norway? A retrospective registry study.

ABSTRACT:

Objectives

The objective of this study was to investigate the use of, and predictors for, pharmaceutical anticancer treatment (PACT) towards the end of a patient's life in a country with a public healthcare system.

Design

Retrospective registry study.

Setting

Secondary care in Norway.

Participants

All Norwegian patients with cancer (International Classification of Diseases tenth revision (ICD-10) codes C00-99, D00-09, D37-48) in contact with a somatic hospital in Norway between 2009 and 2017 (N=420 655). Analyses were performed on a subsample of decedents with follow-back time of more than 1 year (2013-2017, N=52 496).

Interventions

N/A.

Primary and secondary outcome measures

Proportion of patients receiving PACT during the last year and month of

SUBMITTER: Bugge C 

PROVIDER: S-EPMC8477316 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature